Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 434-438

  Gomes, Felipe V ^a   Casarotto, Plinio C ^a   Resstel, Leonardo B M ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AM404; Cannabinoids; Marble burying test; Obsessive compulsive disorder; URB597; WIN55,212 2

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; N (4 HYDROXYPHENYL)ARACHIDONAMIDE;

ANIMAL EXPERIMENT; ARTICLE; COMPULSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SCREENING; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; BENZAMIDES; BENZOXAZINES; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; CARBAMATES; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; OBSESSIVE-COMPULSIVE DISORDER; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SYNAPTIC TRANSMISSION;

EID: 79952900893     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.027     Document Type: Article

References (40)

1. Aboujaoude E., Barry J.J., Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009, 29:51-55.
2. Abramowitz J.S., Taylor S., McKay D. Obsessive-compulsive disorder. Lancet 2009, 374:491-499.
3. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
4. Arnold P.D., MacMaster F.P., Richter M.A., Hanna G.L., Sicard T., Burroughs E., et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psych Res Neuroimaging 2009, 172:136-139.
5. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001, 134:845-852.
6. Carlsson M.L. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 2000, 102:401-413.
7. Casarotto P.C., Gomes F.V., Resstel L.B.M., Guimarães F.S. Cannabidiol inhibitory effect on marble burying behaviour: involvement of CB1 receptors. Behav Pharmacol 2010, 21:353-358.
8. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30:1735-1740.
9. Egashira N., Okuno R., Harada S., Matsushita M., Mishima K., Iwasaki K., et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008, 586:164-170.
10. Elphick M.R., Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001, 356:381-408.
11. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001, 298:7-14.
12. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007, 17:761-767.
13. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15:299-304.
14. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990, 87:1932-1936.
15. Hounie A.G., do Rosario-Campos M.C., Diniz J.B., Shavitt R.G., Ferrao Y.A., Lopes A.C., et al. Obsessive-compulsive disorder in Tourette syndrome. Adv Neurol 2006, 99:22-38.
16. Ichimaru Y., Egawa T., Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 1995, 68:65-70.
17. Iijima M., Kurosu S., Chaki S. Effects of agents targeting glutamatergic systems on marble-burying behavior. Neurosci Lett 2010, 471:63-65.
18. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 30:515-527.
19. Jankovic J. Tourette's syndrome. N Engl J Med 2001, 345:1184-1192.
20. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003, 9:76-81.
21. Korff S., Harvey B.H. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am. 2006, 29:371-390.
22. McGrath M.J., Campbell K.M., Parks C.R., Burton F.H. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000, 877:23-30.
23. Moreira F.A., Kaiser N., Monory K., Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54:141-150.
24. Muller-Vahl K.R., Schneider U., Koblenz A., Jobges M., Kolbe H., Daldrup T., et al. Treatment of Tourette's syndrome with delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002, 35:57-61.
25. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991, 38:63-67.
26. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318:304-311.
27. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884.
28. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006, 12:21-38.
29. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
30. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
31. Rodriguez de Fonseca F., Del Arco I., Martin-Calderon J.L., Gorriti M.A., Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998, 5:483-501.
32. Rutkowska M., Jamontt J., Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 2006, 58:200-206.
33. Sanudo-Pena M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. Eur J Pharmacol 2000, 391:269-274.
34. Schindler F., Anghelescu I., Regen F., Jockers-Scherubl M. Improvement in refractory obsessive compulsive disorder with dronabinol. Am J Psychiatry 2008, 165:536-537.
35. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001, 22:565-572.
36. Thomas A., Burant A., Bui N., Graham D., Yuva-Paylor L.A., Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 2009, 204:361-373.
37. Ting J.T., Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008, 2:62-75.
38. Umathe S.N., Manna S.S., Utturwar K.S., Jain N.S. Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1191-1199.
39. Varvel S.A., Bridgen D.T., Tao Q., Thomas B.F., Martin B.R., Lichtman A.H. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 2005, 314:329-337.
40. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.